Merus N.V. (NASDAQ:MRUS) and Partner Therapeutics Inc, a private biotechnology company focused on hematology and oncology, ...

Biocon Biologics has secured USFDA approval to launch the biosimilar of Janssen's Stelara by February 2025, targeting ...

The FDA granted approval to nilotinib (Danziten) on November 14, 2024, for the treatment of adult patients with newly ...

Replimune's BLA submission and promising pipeline drugs are set to impact the global melanoma therapeutics market. Read more ...

Ferring Announces U.S. FDA Advisory Committee Meeting for SI-6603 (condoliase), An Investigational Treatment in Lumbar Disc ...

Monday announced an agreement with Partner Therapeutics, Inc. to commercialize Zenocutuzumab for the treatment of ...

N.V. and Partner Therapeutics, Inc., a private, fully-integrated biotechnology company with a focus in hematology and oncology, announced they have entered into an agreement in which Merus has ...

The FDA has received a biologics license application submission for RP1 plus nivolumab in patients with PD-1 ...

Johnson & Johnson has announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and ...

Outlook said it remains confident that ONS-5010, marketed as Lytenava in the EU, is an important therapy for the treatment of wet age-related macular degeneration in place of off-label repackaged ...

London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review a Biologics License ...

The approval is supported by data from the COBLT study, FDA dockets and public information, and an observational database.